39.93

3.40% 1.3135

Palvella Therapeutics Inc (PVLA)

Overview News Price History Discussions Forecast

Palvella Therapeutics Inc stock is traded at $39.93, with a volume of 75,362. It is up +3.40% in the last 24 hours and up +80.86% over the past month. Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.

Previous Close:

$38.62

Open:

$39.05

24h Volume:

75,362

Relative Volume:

0.69

Market Cap:

$432.55M

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+28.82%

1M Performance:

+80.86%

6M Performance:

+215.68%

1Y Performance:

+0.00%

1-Day Range:

$37.70

$40.00

1-Week Range:

$31.01

$40.00

52-Week Range:

$11.17

$40.00

Palvella Therapeutics Inc Stock (PVLA) Company Profile

Name

Palvella Therapeutics Inc

Sector

Healthcare (1167)

Industry

Biotechnology (651)

Phone

(484) 253-1461

Address

125 STRAFFORD AVE, WAYNE

Employee

Twitter

Next Earnings Date

Latest SEC Filings

PVLA's Discussions on Twitter

Compare PVLA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PVLA Palvella Therapeutics Inc	39.12	426.97M	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	467.12	120.60B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	565.95	60.80B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	327.76	42.87B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	596.51	36.23B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	297.79	31.54B	3.81B	-644.79M	-669.77M	-6.24

Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-21-25	Initiated	Truist	Buy
Apr-09-25	Initiated	Chardan Capital Markets	Buy
Mar-26-25	Initiated	Stifel	Buy
Mar-07-25	Initiated	Scotiabank	Sector Outperform
Feb-20-25	Initiated	Canaccord Genuity	Buy
Feb-05-25	Initiated	TD Cowen	Buy
Dec-26-24	Initiated	H.C. Wainwright	Buy
Dec-18-24	Initiated	Cantor Fitzgerald	Overweight
Mar-13-20	Upgrade	Robert W. Baird	Neutral → Outperform
Jul-30-19	Downgrade	Robert W. Baird	Outperform → Neutral
May-14-19	Initiated	Robert W. Baird	Outperform
Mar-19-18	Initiated	Evercore ISI	Outperform
Mar-19-18	Initiated	Jefferies	Buy
Jan-16-18	Reiterated	H.C. Wainwright	Buy
May-30-17	Initiated	Rodman & Renshaw	Buy
Aug-05-16	Resumed	ROTH Capital	Buy
Aug-12-15	Initiated	JMP Securities	Mkt Outperform
Jul-27-15	Initiated	Oppenheimer	Outperform
Jul-22-15	Initiated	ROTH Capital	Buy

View All

Palvella Therapeutics Inc Stock (PVLA) Latest News

07:29 AM

Palvella Therapeutics Inc. stock trend forecastFree Community Entry Consensus Trade Ideas - Newser

07:29 AM

06:21 AM

When is Palvella Therapeutics Inc. stock expected to show significant growthFree Investment Case Studies - jammulinksnews.com

06:21 AM

05:30 AM

Ranking Palvella Therapeutics Inc. among high performing stocks via tools Investment Life Cycle Planning Summary - Newser

05:30 AM

12:53 PM

Should I hold or sell Palvella Therapeutics Inc. stock in 2025Free Consultation - jammulinksnews.com

12:53 PM

Jul 27, 2025

How does Palvella Therapeutics Inc. generate profit in a changing economyExplosive earning power - jammulinksnews.com

Jul 27, 2025

What catalysts could drive Palvella Therapeutics Inc. stock higher in 2025Capital growth strategies that work - jammulinksnews.com

Jul 27, 2025

How does Palvella Therapeutics Inc. compare to its industry peersCapitalize on strong market momentum - jammulinksnews.com

Jul 27, 2025

Is Palvella Therapeutics Inc. stock overvalued or undervaluedDiscover stocks with superior performance - jammulinksnews.com

Jul 27, 2025

What is the risk reward ratio of investing in Palvella Therapeutics Inc. stockTremendous financial leverage - jammulinksnews.com

Jul 27, 2025

Key External Factors That Drive Palvella Therapeutics Inc. Stock Price MovementsMassive Profit Potential - Newser

Jul 27, 2025

What makes Palvella Therapeutics Inc. stock price move sharplyEarly Breakout Tracker - Newser

Jul 27, 2025

Will Palvella Therapeutics Inc. stock split in the near futureFree Stock Index Interpretation - Newser

Jul 27, 2025

Will Palvella Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsBreakout Confirmation Tool - Newser

Jul 27, 2025

Is it the right time to buy Palvella Therapeutics Inc. stockIdentify undervalued stocks poised to rally - jammulinksnews.com

Jul 27, 2025

Top Risks to Consider Before Buying Palvella Therapeutics Inc. StockFree Stock Market Knowledge Sharing - Newser

Jul 27, 2025

Palvella Therapeutics Inc. Stock Performance After Earnings: Historical InsightsMinimized Risk Maximum Return - Newser

Jul 27, 2025

Top Risks to Consider Before Buying Palvella Therapeutics Inc. Stock Free Consistent Gain Investment Strategies - Newser

Jul 27, 2025

Jul 25, 2025

Palvella Therapeutics Inc. Stock Analysis and ForecastConsistently outstanding ROI - PrintWeekIndia

Jul 25, 2025

What drives Palvella Therapeutics Inc. stock priceUnprecedented profit potential - Autocar Professional

Jul 25, 2025

Is Palvella Therapeutics Inc. a good long term investmentFree Capital Allocation Plans - PrintWeekIndia

Jul 25, 2025

Why Palvella Therapeutics Inc. stock attracts strong analyst attentionSafer Investing With Bigger Upside - Newser

Jul 25, 2025

Jul 24, 2025

Should I buy Palvella Therapeutics Inc. stock before earningsTriple-digit wealth increases - jammulinksnews.com

Jul 24, 2025

Jul 23, 2025

What analysts say about Palvella Therapeutics Inc. stockStrong return on investment - Autocar Professional

Jul 23, 2025

A Great Week for Institutional Investors Who Own 27% of Palvella Therapeutics, Inc. (NASDAQ:PVLA) - 富途牛牛

Jul 23, 2025